Triclabendazole

• Description:

  Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME) -dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica[1][2][3].

• Product Name Alternative:

  CGA89317

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Bcl-2 Family; Caspase; Parasite; PARP; Pyroptosis

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/triclabendazole.html

• Purity:

  99.36

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CSC1=NC2=CC(OC3=CC=CC(Cl)=C3Cl)=C(Cl)C=C2N1

• Molecular Formula:

  C14H9Cl3N2OS

• Molecular Weight:

  359.66

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Yan L, et al. Triclabendazole induces pyroptosis by activating caspase-3 to cleave GSDME in breast cancer cells [J]. Frontiers in Pharmacology, 2021, 12: 670081.|[2]Devine C, et al. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole [J]. Veterinary parasitology, 2012, 184 (1) : 37-47.|[3]Borges B S, et al. In vitro anti-Leishmania activity of triclabendazole and its synergic effect with amphotericin B [J]. Frontiers in Cellular and Infection Microbiology, 2023, 12: 1044665.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  Bax; Bcl-2; Caspase 3; Caspase 8; Caspase 9; Leishmania; PARP

• CAS Number:

  [68786-66-3]